| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
CCR2 antagonist 3 targets the chemokine receptor 2 (CCR2). It is an antagonist that blocks the receptor and prevents the corresponding chemokines from exerting their effects on immune cells, leading to reduced chemotaxis and cell activation.
|
|---|---|
| ln Vitro |
In vitro, CCR2 antagonist 3 blocks the CCR2 receptor, inhibiting chemotaxis and cell activation. It is used to investigate the interruption of CCR2, which may have roles in inflammatory and related conditions.
|
| ln Vivo |
In vivo activity of CCR2 antagonist 3 has not been detailed in the provided search results. As a CCR2 antagonist, it would be expected to reduce monocyte recruitment and inflammatory responses in animal models of inflammation.
|
| Enzyme Assay |
In vitro receptor binding assays measure the compound's affinity for CCR2. These assays typically involve competition binding with a radiolabeled CCR2 ligand using membrane preparations from cells expressing the receptor.
|
| Cell Assay |
In vitro cell-based assays measure the compound's ability to inhibit chemotaxis. Cells expressing CCR2 are placed in a chemotaxis chamber, and their migration towards a chemokine ligand, such as CCL2, is measured in the presence or absence of the compound.
|
| Animal Protocol |
In vivo animal studies have not been detailed in the provided search results. CCR2 antagonists are typically studied in animal models of inflammatory diseases, such as arthritis, atherosclerosis, or multiple sclerosis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of CCR2 antagonist 3 have not been detailed in the provided search results. It is soluble in DMSO at ~100 mg/mL.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CCR2 antagonist 3 has not been detailed in the provided search results. The compound is for research use only. It is supplied as a white to off-white solid powder with a purity of ≥98%.
|
| Additional Infomation |
CCR2 antagonist 3 is supplied as a solid powder. The product is for research use only and not for human use.
|
| Molecular Formula |
C17H25FN2O2
|
|---|---|
| Molecular Weight |
308.391008138657
|
| Exact Mass |
308.19
|
| CAS # |
1380100-86-6
|
| PubChem CID |
57345449
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C=CC(=CC=1C)C(N(C)[C@@H](C(C)C)CN1CC(C1)O)=O
|
| InChi Key |
GAHPWXLXWUVMIV-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C17H25FN2O2/c1-11(2)16(10-20-8-14(21)9-20)19(4)17(22)13-5-6-15(18)12(3)7-13/h5-7,11,14,16,21H,8-10H2,1-4H3/t16-/m1/s1
|
| Chemical Name |
4-fluoro-N-[(2S)-1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl]-N,3-dimethylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~324.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2426 mL | 16.2132 mL | 32.4265 mL | |
| 5 mM | 0.6485 mL | 3.2426 mL | 6.4853 mL | |
| 10 mM | 0.3243 mL | 1.6213 mL | 3.2426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
